OBJECTIVE: The overall prognosis of ovarian carcinoma is poor. However, the outcome of apparently similar cases is highly variable, and molecular markers that would predict disease outcome in a clinically useful manner are lacking. We investigated the value of p53 expression as a disease determinant in serous carcinoma, which is the most common type of ovarian carcinoma and has shown the highest frequency of p53 alterations. METHODS: Tissue microarray constructed of 522 serous ovarian carcinomas was examined immunohistochemically using DO-7 monoclonal antibody against p53 protein. The findings were correlated with overall and disease-free survival, response to therapy, and clinicopathological characteristics of the patients. RESULTS: Both excessive and completely negative p53 staining confered poor patient outcome and were considered aberrant p53 expression. Patients with aberrant p53 (59% of the carcinomas) showed 5-year overall survival of 26% (20-31%), whereas patients with normal p53 expression (41% of the carcinomas) showed 5-year overall survival of 79% (95% CI, 74-85%) (P < 0.0001). The association of aberrant p53 with poor prognosis was independent of clinicopathological parameters, e.g., stage and grade. In addition, aberrant p53 status was significantly associated with shorter disease-free survival (P < 0.0001) and poor response to therapy (P < 0.0001). In the most common subgroups, stage III and stage I carcinomas, 5-year overall survival rates for patients showing normal p53 vs. aberrant p53 were 72% vs. 19% (P < 0.0001) and 99% vs. 56% (P < 0.0001), respectively. CONCLUSION: P53 expression status divides serous ovarian carcinomas into two distinct subtypes: one with a relatively good prognosis and the other with a particularly poor outcome.
OBJECTIVE: The overall prognosis of ovarian carcinoma is poor. However, the outcome of apparently similar cases is highly variable, and molecular markers that would predict disease outcome in a clinically useful manner are lacking. We investigated the value of p53 expression as a disease determinant in serous carcinoma, which is the most common type of ovarian carcinoma and has shown the highest frequency of p53 alterations. METHODS: Tissue microarray constructed of 522 serous ovarian carcinomas was examined immunohistochemically using DO-7 monoclonal antibody against p53 protein. The findings were correlated with overall and disease-free survival, response to therapy, and clinicopathological characteristics of the patients. RESULTS: Both excessive and completely negative p53 staining confered poor patient outcome and were considered aberrant p53 expression. Patients with aberrant p53 (59% of the carcinomas) showed 5-year overall survival of 26% (20-31%), whereas patients with normal p53 expression (41% of the carcinomas) showed 5-year overall survival of 79% (95% CI, 74-85%) (P < 0.0001). The association of aberrant p53 with poor prognosis was independent of clinicopathological parameters, e.g., stage and grade. In addition, aberrant p53 status was significantly associated with shorter disease-free survival (P < 0.0001) and poor response to therapy (P < 0.0001). In the most common subgroups, stage III and stage I carcinomas, 5-year overall survival rates for patients showing normal p53 vs. aberrant p53 were 72% vs. 19% (P < 0.0001) and 99% vs. 56% (P < 0.0001), respectively. CONCLUSION:P53 expression status divides serous ovarian carcinomas into two distinct subtypes: one with a relatively good prognosis and the other with a particularly poor outcome.
Authors: Jia Huang; Lin Zhang; Joel Greshock; Theresa A Colligon; Yan Wang; Renee Ward; Dionyssios Katsaros; Heini Lassus; Ralf Butzow; Andrew K Godwin; Joseph R Testa; Katherine L Nathanson; Phyllis A Gimotty; George Coukos; Barbara L Weber; Yan Degenhardt Journal: Genes Chromosomes Cancer Date: 2011-05-11 Impact factor: 5.006
Authors: Heini Lassus; Harri Sihto; Arto Leminen; Heikki Joensuu; Jorma Isola; Nina N Nupponen; Ralf Butzow Journal: J Mol Med (Berl) Date: 2006-04-11 Impact factor: 4.599
Authors: S Dholariya; R Mir; M Zuberi; P Yadav; G Gandhi; N Khurana; A Saxena; P C Ray Journal: Clin Transl Oncol Date: 2015-07-25 Impact factor: 3.405
Authors: Isabelle J Létourneau; Michael C J Quinn; Lu-Lin Wang; Lise Portelance; Katia Y Caceres; Louis Cyr; Nathalie Delvoye; Liliane Meunier; Manon de Ladurantaye; Zhen Shen; Suzanna L Arcand; Patricia N Tonin; Diane M Provencher; Anne-Marie Mes-Masson Journal: BMC Cancer Date: 2012-08-29 Impact factor: 4.430
Authors: C Böckelman; H Lassus; A Hemmes; A Leminen; J Westermarck; C Haglund; R Bützow; A Ristimäki Journal: Br J Cancer Date: 2011-09-06 Impact factor: 7.640
Authors: Ingiridur Skirnisdottir; Markus Mayrhofer; Maria Rydåker; Helena Akerud; Anders Isaksson Journal: BMC Cancer Date: 2012-09-12 Impact factor: 4.430